Ribera, JordiGranada, IsabelMorgades, MireiaVives, SusanaGenescà, EulàliaGonzález, CeliaNomdedeu, JosepEscoda, LourdesMontesinos, PauMercadal, SantiagoColl, RosaGonzález-Campos, JoséAbella, EugeniaBarba, PereBermúdez, AranchaGil, CristinaTormo, MarPedreño, MaríaMartínez-Carballeira, DanielHernández-Rivas, Jesús-MaríaOrfao, AlbertoMartínez-López, JoaquínEsteve, JordiBravo, PilarGarcia-Guiñon, AntoniDebén, GuillermoMoraleda, José MQueizán, José AOrtín, XavierMoreno, María JFeliu, EvaristSolé, FrancescRibera, Josep MPETHEMA Group, Spanish Society of Haematology2023-01-252023-01-252019-03-27http://hdl.handle.net/10668/13761The prognostic significance of low-hypodiploidy has not been extensively evaluated in minimal residual disease (MRD)-oriented protocols for adult acute lymphoblastic leukaemia (ALL). We analysed the outcome of hypodiploid adult ALL patients treated within Programa Español de Tratamientos en Hematología (PETHEMA) protocols. The 5-year cumulative incidence of relapse (CIR) of low-hypodiploid B-cell precursor (BCP)-ALL was significantly higher than that of high-hypodiploids (52% vs. 12%, P = 0.013). Low-hypodiploid BCP-ALL patients aged ≤35 years showed superior survival (71% vs. 21%, P = 0.026) and lower 5-year CIR (17% vs. 66%, P = 0.090) than low-hypodiploids aged >35 years. Older adults and elderly low-hypodiploid BCP-ALL patients show dismal prognosis although achieving an end-induction good MRD response.enacute lymphoblastic leukaemiaadultsagehypodiploidyprognosisAdolescentAdultAge FactorsAgedDisease-Free SurvivalFemaleHumansIncidenceMaleMiddle AgedNeoplasm, ResidualPloidiesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesSurvival Rateresearch article30916384open access10.1111/bjh.158871365-2141https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.15887